Inhibition of the covalent binding reaction of complement component C4 by penicillamine, an anti-rheumatic agent.
D(-)-Penicillamine [D(-)-beta beta-dimethylcysteine] is an anti-arthritic drug, but its use is limited by adverse side effects, which include problems in immune-complex clearance. Complement is important as a source of inflammatory mediators in rheumatoid arthritis and is also involved in immune-complex clearance. Thus inhibition of the complement cascade would be likely to contribute to both the therapeutic and the toxic effects of penicillamine. It is shown that penicillamine and cysteine are potent inhibitors of the covalent binding of activated complement component C4 to immune complexes. [35S]Cysteine itself becomes covalently bound to C4b through the thioester site. Penicillamine and cysteine are more reactive with the C4A isotype than with the C4B isotype of the HLA class III protein C4. The limited amino acid sequence differences between C4A and C4B include a cysteine/serine interchange, and it is suggested that the cysteine residue in C4A contributes to the increased rate of reaction of C4A with the alpha-amino-beta-thiol compounds.
Sim
E
E
Department of Pharmacology, University of Oxford, U.K.
Dodds
A W
AW
Goldin
A
A
D000706:Anaphylatoxins / Q000037:antagonists & inhibitors; D003181:Complement C4 / Q000037:antagonists & inhibitors*; D015934:Complement C4a; D015935:Complement C4b; D003171:Complement Pathway, Classical / Q000187:drug effects; D003545:Cysteine / Q000276:immunology / Q000494:pharmacology; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D010396:Penicillamine / Q000494:pharmacology*
D000706:Anaphylatoxins; D003181:Complement C4; D015934:Complement C4a; D015935:Complement C4b; D010396:Penicillamine; D003545:Cysteine